Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Cannabis Bioscience International Holdings EBITDA Margin %?
Cannabis Bioscience International HoldingsCBIH +33.33% EBITDA Margin % is -845.45% as of Feb. 2026. The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Cannabis Bioscience International Holdings ranks worse than 94.07% on this metric.
Cannabis Bioscience International Holdings (OTCPK:CBIH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cannabis Bioscience International Holdings EBITDA Margin % Related Terms
Cannabis Bioscience International Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannabis Bioscience International Holdings EBITDA Margin % Chart
Cannabis Bioscience International Holdings Annual Data
CBIH vs SXTC, UPC, NPHC: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannabis Bioscience International Holdings EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannabis Bioscience International Holdings (CBIH) has a EBITDA Margin % of -845.45% as of Feb. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cannabis Bioscience International Holdings and its competitors. According to the industry distribution chart, Cannabis Bioscience International Holdings ranks #904 out of 961 companies in the Drug Manufacturers industry, placing it in the top 94.1%.
Is Cannabis Bioscience International Holdings' EBITDA Margin % too high?
Cannabis Bioscience International Holdings' current EBITDA Margin % is -845.45%. Based on the distribution chart, Cannabis Bioscience International Holdings ranks #904 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Cannabis Bioscience International Holdings' EBITDA Margin % compare to SXTC and UPC?
According to the Drug Manufacturers industry distribution chart, Cannabis Bioscience International Holdings ranks #904 out of 961 companies for EBITDA Margin %. This places Cannabis Bioscience International Holdings in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cannabis Bioscience International Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabis Bioscience International Holdings's current EBITDA Margin % is -845.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Bioscience International Holdings stock overvalued right now?
Cannabis Bioscience International Holdings (CBIH) has a current EBITDA Margin % of -845.45%. The current EBITDA Margin % is -845.45%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cannabis Bioscience International Holdings (CBIH), the current EBITDA Margin % is -845.45% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cannabis Bioscience International Holdings Inc operates in three main areas. Firstly, the company engages in cannabis-related research and education under the trade name Pharmacology University. Secondly, it serves as both a Sponsor and a Contract Research Organization (CRO) in clinical trials, some of which involve cannabis and CBD products, under the trade name Alpha Research Institute. Lastly, the company plans to manufacture, market, and sell CBD products branded as "VitaCookies." The majority of the company's revenue comes from clinical trial contracts, while a smaller portion is generated from cannabis-related educational classes and seminars.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBIH has been successfully added to your 
